Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer

Mark P. G. Dings; Paul Manoukian; Cynthia Waasdorp; Judith S. E. Quik; Marin Strijker; Sophie C. Lodestijn; Sanne M. van Neerven; Leandro F. Moreno; Rodrigo Leite de Oliveira; Bert A. Bonsing; Marco J. Bruno; Olivier R. Busch; Michael Doukas; Casper H. van Eijck; Nadia Haj Mohammad; Ignace H. de Hingh; Quintus Molenaar; Marc G. Besselink; Louis Vermeulen; Jan Paul Medema; Hanneke W. M. van Laarhoven; Maarten F. Bijlsma

doi:10.1002/ijc.34276

Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer

Mark P. G. Dings
, Paul Manoukian
, Cynthia Waasdorp
, Judith S. E. Quik
, Marin Strijker
, Sophie C. Lodestijn
, Sanne M. van Neerven
, Leandro F. Moreno
, Rodrigo Leite de Oliveira
, Bert A. Bonsing
, Marco J. Bruno
, Olivier R. Busch
, Michael Doukas
, Casper H. van Eijck
, Nadia Haj Mohammad
, Ignace H. de Hingh
, Quintus Molenaar
, Marc G. Besselink
, Louis Vermeulen
, Jan Paul Medema

Hanneke W. M. van Laarhoven, Maarten F. Bijlsma^*

^*Corresponding author for this work

Vrije Universiteit Amsterdam
Center for Experimental Molecular Medicine (CEMM)
Amsterdam UMC, Locatie UvA/AMC
Leiden University Medical Centre
University Medical Centre Utrecht
Catharina Hospital
St. Antonius Ziekenhuis

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Web of Science)

423 Downloads (Pure)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma, the main cellular constituents of which are cancer-associated fibroblasts (CAFs). Stroma-targeting agents have been proposed to improve the poor outcome of current treatments. However, clinical trials using these agents showed disappointing results. Heterogeneity in the PDAC CAF population was recently delineated demonstrating that both tumor-promoting and tumor-suppressive activities co-exist in the stroma. Here, we aimed to identify biomarkers for the CAF population that contribute to a favorable outcome. RNA-sequencing reads from patient-derived xenografts (PDXs) were mapped to the human and mouse genome to allocate the expression of genes to the tumor or stroma. Survival meta-analysis for stromal genes was performed and applied to human protein atlas data to identify circulating biomarkers. The candidate protein was perturbed in co-cultures and assessed in existing and novel single-cell gene expression analysis from control, pancreatitis, pancreatitis-recovered and PDAC mouse models. Serum levels of the candidate biomarker were measured in two independent cohorts totaling 148 PDAC patients and related them to overall survival. Osteoglycin (OGN) was identified as a candidate serum prognostic marker. Single-cell analysis indicated that Ogn is derived from a subgroup of inflammatory CAFs. Ogn-expressing fibroblasts are distinct from resident healthy pancreatic stellate cells and arise during pancreatitis. Serum OGN levels were prognostic for favorable overall survival in two independent PDAC cohorts (HR = 0.47, P = .042 and HR = 0.53, P = .006). Altogether, we conclude that high circulating OGN levels inform on a previously unrecognized subgroup of CAFs and predict favorable outcomes in resectable PDAC.

Original language	English
Pages (from-to)	511-523
Number of pages	13
Journal	International Journal of Cancer
Volume	152
Issue number	3
Early online date	19 Sept 2022
DOIs	https://doi.org/10.1002/ijc.34276
Publication status	Published - 1 Feb 2023

Bibliographical note

Funding Information:
Maarten F. Bijlsma has received research funding from Celgene, Frame Therapeutics and LeadPharma, and has acted as a consultant to Servier. Hanneke W. M. van Laarhoven has served as a consultant for BMS, Dragonfly, Lilly, Merck, Nordic Pharma and Servier, and has received unrestricted research funding and/or study medication from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche and Servier, and has been a speaker for Astellas and Novartis. Jan Paul Medema has acted as a consultant to AbbVie. Louis Vermeulen received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre. None of these parties were involved in the design of our study or drafting of the study. The other authors have no conflict of interest to declare.

Funding Information:
The authors would like to thank the patients for participating, and to the Liquid Biopsy Center, Mai Tran, Melissa Fidder, Dr Michiel Pegtel for sample acquisition and logistical support. Funding was provided by KWF Dutch Cancer Society, the AMC Foundation, the CCA Foundation, H2020‐MSCA‐ITN 861196 PRECODE and Oncode.

Publisher Copyright:
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/ijc.34276Licence: CC BY-NC

Intl Journal of Cancer - 2022 - Dings - Serum levels of iCAF‐derived osteoglycin predict favorable outcome in pancreaticFinal published version, 1.65 MBLicence: CC BY-NC

Cite this

Dings, M. P. G., Manoukian, P., Waasdorp, C., Quik, J. S. E., Strijker, M., Lodestijn, S. C., van Neerven, S. M., Moreno, L. F., de Oliveira, R. L., Bonsing, B. A., Bruno, M. J., Busch, O. R., Doukas, M., van Eijck, C. H., Mohammad, N. H., de Hingh, I. H., Molenaar, Q., Besselink, M. G., Vermeulen, L., ... Bijlsma, M. F. (2023). Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. International Journal of Cancer, 152(3), 511-523. https://doi.org/10.1002/ijc.34276

@article{4e1ed1ff157e4175868e0238266dcf34,

title = "Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma, the main cellular constituents of which are cancer-associated fibroblasts (CAFs). Stroma-targeting agents have been proposed to improve the poor outcome of current treatments. However, clinical trials using these agents showed disappointing results. Heterogeneity in the PDAC CAF population was recently delineated demonstrating that both tumor-promoting and tumor-suppressive activities co-exist in the stroma. Here, we aimed to identify biomarkers for the CAF population that contribute to a favorable outcome. RNA-sequencing reads from patient-derived xenografts (PDXs) were mapped to the human and mouse genome to allocate the expression of genes to the tumor or stroma. Survival meta-analysis for stromal genes was performed and applied to human protein atlas data to identify circulating biomarkers. The candidate protein was perturbed in co-cultures and assessed in existing and novel single-cell gene expression analysis from control, pancreatitis, pancreatitis-recovered and PDAC mouse models. Serum levels of the candidate biomarker were measured in two independent cohorts totaling 148 PDAC patients and related them to overall survival. Osteoglycin (OGN) was identified as a candidate serum prognostic marker. Single-cell analysis indicated that Ogn is derived from a subgroup of inflammatory CAFs. Ogn-expressing fibroblasts are distinct from resident healthy pancreatic stellate cells and arise during pancreatitis. Serum OGN levels were prognostic for favorable overall survival in two independent PDAC cohorts (HR = 0.47, P = .042 and HR = 0.53, P = .006). Altogether, we conclude that high circulating OGN levels inform on a previously unrecognized subgroup of CAFs and predict favorable outcomes in resectable PDAC.",

author = "Dings, \{Mark P. G.\} and Paul Manoukian and Cynthia Waasdorp and Quik, \{Judith S. E.\} and Marin Strijker and Lodestijn, \{Sophie C.\} and \{van Neerven\}, \{Sanne M.\} and Moreno, \{Leandro F.\} and \{de Oliveira\}, \{Rodrigo Leite\} and Bonsing, \{Bert A.\} and Bruno, \{Marco J.\} and Busch, \{Olivier R.\} and Michael Doukas and \{van Eijck\}, \{Casper H.\} and Mohammad, \{Nadia Haj\} and \{de Hingh\}, \{Ignace H.\} and Quintus Molenaar and Besselink, \{Marc G.\} and Louis Vermeulen and Medema, \{Jan Paul\} and \{van Laarhoven\}, \{Hanneke W. M.\} and Bijlsma, \{Maarten F.\}",

note = "Funding Information: Maarten F. Bijlsma has received research funding from Celgene, Frame Therapeutics and LeadPharma, and has acted as a consultant to Servier. Hanneke W. M. van Laarhoven has served as a consultant for BMS, Dragonfly, Lilly, Merck, Nordic Pharma and Servier, and has received unrestricted research funding and/or study medication from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche and Servier, and has been a speaker for Astellas and Novartis. Jan Paul Medema has acted as a consultant to AbbVie. Louis Vermeulen received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre. None of these parties were involved in the design of our study or drafting of the study. The other authors have no conflict of interest to declare. Funding Information: The authors would like to thank the patients for participating, and to the Liquid Biopsy Center, Mai Tran, Melissa Fidder, Dr Michiel Pegtel for sample acquisition and logistical support. Funding was provided by KWF Dutch Cancer Society, the AMC Foundation, the CCA Foundation, H2020‐MSCA‐ITN 861196 PRECODE and Oncode. Publisher Copyright: {\textcopyright} 2022 The Authors. International Journal of Cancer published by John Wiley \& Sons Ltd on behalf of UICC.",

year = "2023",

month = feb,

day = "1",

doi = "10.1002/ijc.34276",

language = "English",

volume = "152",

pages = "511--523",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley \& Sons Inc.",

number = "3",

}

Dings, MPG, Manoukian, P, Waasdorp, C, Quik, JSE, Strijker, M, Lodestijn, SC, van Neerven, SM, Moreno, LF, de Oliveira, RL, Bonsing, BA, Bruno, MJ, Busch, OR, Doukas, M , van Eijck, CH, Mohammad, NH, de Hingh, IH, Molenaar, Q, Besselink, MG, Vermeulen, L, Medema, JP, van Laarhoven, HWM & Bijlsma, MF 2023, 'Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer', International Journal of Cancer, vol. 152, no. 3, pp. 511-523. https://doi.org/10.1002/ijc.34276

TY - JOUR

T1 - Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer

AU - Dings, Mark P. G.

AU - Manoukian, Paul

AU - Waasdorp, Cynthia

AU - Quik, Judith S. E.

AU - Strijker, Marin

AU - Lodestijn, Sophie C.

AU - van Neerven, Sanne M.

AU - Moreno, Leandro F.

AU - de Oliveira, Rodrigo Leite

AU - Bonsing, Bert A.

AU - Bruno, Marco J.

AU - Busch, Olivier R.

AU - Doukas, Michael

AU - van Eijck, Casper H.

AU - Mohammad, Nadia Haj

AU - de Hingh, Ignace H.

AU - Molenaar, Quintus

AU - Besselink, Marc G.

AU - Vermeulen, Louis

AU - Medema, Jan Paul

AU - van Laarhoven, Hanneke W. M.

AU - Bijlsma, Maarten F.

N1 - Funding Information: Maarten F. Bijlsma has received research funding from Celgene, Frame Therapeutics and LeadPharma, and has acted as a consultant to Servier. Hanneke W. M. van Laarhoven has served as a consultant for BMS, Dragonfly, Lilly, Merck, Nordic Pharma and Servier, and has received unrestricted research funding and/or study medication from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche and Servier, and has been a speaker for Astellas and Novartis. Jan Paul Medema has acted as a consultant to AbbVie. Louis Vermeulen received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre. None of these parties were involved in the design of our study or drafting of the study. The other authors have no conflict of interest to declare. Funding Information: The authors would like to thank the patients for participating, and to the Liquid Biopsy Center, Mai Tran, Melissa Fidder, Dr Michiel Pegtel for sample acquisition and logistical support. Funding was provided by KWF Dutch Cancer Society, the AMC Foundation, the CCA Foundation, H2020‐MSCA‐ITN 861196 PRECODE and Oncode. Publisher Copyright: © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma, the main cellular constituents of which are cancer-associated fibroblasts (CAFs). Stroma-targeting agents have been proposed to improve the poor outcome of current treatments. However, clinical trials using these agents showed disappointing results. Heterogeneity in the PDAC CAF population was recently delineated demonstrating that both tumor-promoting and tumor-suppressive activities co-exist in the stroma. Here, we aimed to identify biomarkers for the CAF population that contribute to a favorable outcome. RNA-sequencing reads from patient-derived xenografts (PDXs) were mapped to the human and mouse genome to allocate the expression of genes to the tumor or stroma. Survival meta-analysis for stromal genes was performed and applied to human protein atlas data to identify circulating biomarkers. The candidate protein was perturbed in co-cultures and assessed in existing and novel single-cell gene expression analysis from control, pancreatitis, pancreatitis-recovered and PDAC mouse models. Serum levels of the candidate biomarker were measured in two independent cohorts totaling 148 PDAC patients and related them to overall survival. Osteoglycin (OGN) was identified as a candidate serum prognostic marker. Single-cell analysis indicated that Ogn is derived from a subgroup of inflammatory CAFs. Ogn-expressing fibroblasts are distinct from resident healthy pancreatic stellate cells and arise during pancreatitis. Serum OGN levels were prognostic for favorable overall survival in two independent PDAC cohorts (HR = 0.47, P = .042 and HR = 0.53, P = .006). Altogether, we conclude that high circulating OGN levels inform on a previously unrecognized subgroup of CAFs and predict favorable outcomes in resectable PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma, the main cellular constituents of which are cancer-associated fibroblasts (CAFs). Stroma-targeting agents have been proposed to improve the poor outcome of current treatments. However, clinical trials using these agents showed disappointing results. Heterogeneity in the PDAC CAF population was recently delineated demonstrating that both tumor-promoting and tumor-suppressive activities co-exist in the stroma. Here, we aimed to identify biomarkers for the CAF population that contribute to a favorable outcome. RNA-sequencing reads from patient-derived xenografts (PDXs) were mapped to the human and mouse genome to allocate the expression of genes to the tumor or stroma. Survival meta-analysis for stromal genes was performed and applied to human protein atlas data to identify circulating biomarkers. The candidate protein was perturbed in co-cultures and assessed in existing and novel single-cell gene expression analysis from control, pancreatitis, pancreatitis-recovered and PDAC mouse models. Serum levels of the candidate biomarker were measured in two independent cohorts totaling 148 PDAC patients and related them to overall survival. Osteoglycin (OGN) was identified as a candidate serum prognostic marker. Single-cell analysis indicated that Ogn is derived from a subgroup of inflammatory CAFs. Ogn-expressing fibroblasts are distinct from resident healthy pancreatic stellate cells and arise during pancreatitis. Serum OGN levels were prognostic for favorable overall survival in two independent PDAC cohorts (HR = 0.47, P = .042 and HR = 0.53, P = .006). Altogether, we conclude that high circulating OGN levels inform on a previously unrecognized subgroup of CAFs and predict favorable outcomes in resectable PDAC.

UR - https://www.scopus.com/pages/publications/85138278433

U2 - 10.1002/ijc.34276

DO - 10.1002/ijc.34276

M3 - Article

C2 - 36069222

SN - 0020-7136

VL - 152

SP - 511

EP - 523

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 3

ER -

Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this